Peptide questions · Survodutide

How long does survodutide take to work?

Reviewed Evidence: EstablishedPublished by PepVault

Survodutide’s onset is days–2 weeks, its peak effect comes at 76 weeks (trial endpoint), and its typical duration is ongoing, by the library’s timeline (backed by clinical trial data).

The timeline’s basis: Phase 2 RCT (le Roux 2024); phase 3 SYNCHRONIZE-1 and -2 (NEJM 2026) and SYNCHRONIZE-MASLD (Nat Med 2026). Not approved.

Survodutide week by week

The library places five of its research notes on survodutide on the days they cover, from day 1 to day 336 and on: 5 on randomized trials.

Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.

The survodutide notes by day
WhenThe noteEvidence
Days 1–14 (weeks 1–2)The 0.3 mg startRandomized trial
Days 15–168 (weeks 3–24)The slow climbRandomized trial
From day 99 on3.6 mg, the lower phase 3 doseRandomized trial
From day 141 on6.0 mg, the top phase 3 doseRandomized trial
Days 169–336 (weeks 25–48)Liver fat: where the glucagon arm showsRandomized trial
A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Track survodutide in PepVault

Log each dose and your weekly check-ins, and see your own weeks add up.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The survodutide timeline’s milestones

The library’s timeline for survodutide marks 6 points from week 1 to week 76, backed by clinical trial data overall.

  • Week 1: Commonly reported: appetite dipping in the first days on 0.3 mg
  • Week 3: Phase 2 stepped to 0.6 mg here; the phase 3 trials climb more slowly
  • Week 8: Commonly reported: nausea or vomiting after step-ups, easing once a dose holds
  • Week 24: Phase 3 trials reach their maintenance dose, 3.6 or 6.0 mg, around here
  • Week 48: Where its liver trial measured liver fat on MRI
  • Week 76: Where the SYNCHRONIZE weight trials read out

The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.

Why survodutide takes that long

The library states no half-life with a number for survodutide (it says: “Long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries”), so this page can’t work out a build-up; the timing rests on the notes above.

The notes on survodutide follow the trials’ dose steps, 0.3mg, 3.6mg and 6mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.

Survodutide against other metabolic & GLP-1 compounds

The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, survodutide among them; 15 of the others share its onset of days–2 weeks.

When metabolic & GLP-1 compounds start to act and peak, by the library’s timelines
CompoundOnsetPeak effect
SemaglutideDays–2 weeks60–68 weeks
TirzepatideDays–2 weeks72+ weeks
RetatrutideDays–2 weeks48+ weeks
DulaglutideDays–2 weeks24–52 weeks (glucose)
ExenatideFirst dose (after-meal glucose)24–30 weeks (HbA1c)
Setmelanotide1–2 weeks (hunger)52 weeks (BMI)
OrforglipronDays–2 weeks72 weeks (trial endpoint)
SurvodutideDays–2 weeks76 weeks (trial endpoint)
MazdutideDays–2 weeks48–60 weeks
PemvidutideDays–2 weeks48+ weeks
CagrilintideDays–2 weeks26–68 weeks (trial endpoints)
PramlintideFirst meal (fullness, after-meal glucose)16–52 weeks (weight, HbA1c)
CagriSemaDays–2 weeks68+ weeks
EloralintideDays–2 weeks48 weeks (phase 2 endpoint)
PetrelintideDays–2 weeks42 weeks (phase 2, still falling)
AmycretinDays–2 weeks36 weeks (longest trial so far)
VK2735Days–2 weeks78 weeks (phase 3 endpoint, not yet read out)
EnicepatideDays–2 weeks48 weeks (phase 2 endpoint, no plateau)
EcnoglutideDays–2 weeks48 weeks (phase 3, no plateau)
EfinopegdutideWeeks24–52 weeks (trial endpoints)
SLU-PP-332Unknown in peopleUnknown in people

Questions people ask

How long does survodutide take to work?

Survodutide’s onset is days–2 weeks, its peak effect comes at 76 weeks (trial endpoint), and its typical duration is ongoing, by the library’s timeline (backed by clinical trial data).

When does survodutide reach its peak effect?

By the library’s timeline, survodutide’s peak effect comes at 76 weeks (trial endpoint), backed by clinical trial data.

How long is survodutide usually run?

The library’s timeline gives survodutide’s typical duration as ongoing; its cycle note says: Phase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks.

What does the library say about the first days on survodutide?

Its first note on survodutide, for days 1–14 (weeks 1–2), is “The 0.3 mg start”, resting on randomized trials.

More on survodutide

Track it in the app

PepVault for iPhone

Track survodutide in PepVault

Log each dose and your weekly check-ins, and see your own weeks add up.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo